Oculis Holding AG
NASDAQ:OCS
Net Margin
Oculis Holding AG
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
CH |
O
|
Oculis Holding AG
NASDAQ:OCS
|
979.5m USD | N/A | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
735.9B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
404B USD |
25%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
202.1B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
178.4B CHF |
25%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
160.5B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
205.3B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
142.9B USD |
13%
|
Oculis Holding AG
Glance View
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Oculis Holding AG's most recent financial statements, the company has Net Margin of 0%.